Somewhat Favorable Media Coverage Somewhat Unlikely to Impact BiondVax Pharmaceuticals (BVXV) Share Price

News stories about BiondVax Pharmaceuticals (NASDAQ:BVXV) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BiondVax Pharmaceuticals earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 48.952596683368 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Shares of BiondVax Pharmaceuticals (NASDAQ:BVXV) traded up 1.14% during trading on Friday, reaching $7.11. The company had a trading volume of 68,484 shares. BiondVax Pharmaceuticals has a 12 month low of $3.04 and a 12 month high of $8.50. The stock has a 50 day moving average price of $7.20 and a 200 day moving average price of $6.67. The firm’s market capitalization is $28.88 million.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact BiondVax Pharmaceuticals (BVXV) Share Price” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://ledgergazette.com/2017/09/17/biondvax-pharmaceuticals-bvxv-earns-daily-media-sentiment-score-of-0-07.html.

About BiondVax Pharmaceuticals

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.

Insider Buying and Selling by Quarter for BiondVax Pharmaceuticals (NASDAQ:BVXV)

Receive News & Ratings for BiondVax Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply